Takeda Pharmaceutical Company Limited
TKPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,112,796 | $1,106,685 | $1,053,399 | $1,144,124 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Cost of Goods Sold | $380,061 | $384,675 | $382,078 | $416,874 |
| Gross Profit | $732,735 | $722,010 | $671,321 | $727,250 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| R&D Expenses | $161,482 | $143,891 | $216,007 | $170,193 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $253,551 | $255,885 | $295,866 | $270,588 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $248,707 | $137,668 | $234,380 | $219,527 |
| Operating Expenses | $663,740 | $537,444 | $746,253 | $660,308 |
| Operating Income | $68,995 | $184,566 | -$74,932 | $66,942 |
| % Margin | 6.2% | 16.7% | -7.1% | 5.9% |
| Other Income/Exp. Net | -$40,821 | -$33,936 | -$32,367 | -$40,535 |
| Pre-Tax Income | $28,174 | $150,630 | -$107,299 | $26,407 |
| Tax Expense | $39,903 | $26,351 | -$4,201 | $2,572 |
| Net Income | -$11,802 | $124,243 | -$103,155 | $23,789 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS | -7.48 | 79.4 | -65.25 | 15.03 |
| % Growth | -109.4% | 221.7% | -534.1% | – |
| EPS Diluted | -7.48 | 78.23 | -65.25 | 14.78 |
| Weighted Avg Shares Out | 1,577 | 1,565 | 1,582 | 1,583 |
| Weighted Avg Shares Out Dil | 1,577 | 1,588 | 1,582 | 1,610 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44,396 | $73,758 | $8,167 | -$6,988 |
| Interest Expense | $83,138 | $107,158 | $22,430 | $31,596 |
| Depreciation & Amortization | $205,155 | $181,636 | $203,075 | $186,955 |
| EBITDA | $316,467 | $439,424 | $73,346 | $244,958 |
| % Margin | 28.4% | 39.7% | 7% | 21.4% |